Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc. (AARD) priced its initial public offering on Feb 13, 2025 at $16.00 per share, within its $16.00–$18.00 range, raising $94.2M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $342.2M. Paul Hastings advised the company and Cooley advised the underwriters.

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for metabolic diseases that target bitter taste receptors (TAS2Rs) in the gut to address hunger-associated conditions.

Status

IPO

Ticker

AARD

Exchange

Nasdaq Global Select

Priced

Feb 13, 2025

IPO price

$16.00

Price range

$16.00–$18.00

Raised

$94.2M

Market cap at IPO price

$342.2M

First filed

Jan 23, 2025

Company counsel

Paul Hastings

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.